Last reviewed · How we verify
NCT04043858
Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children
NA trial testing Midodrine 2.5 mg tab in Refractory Ascites in 20 participants. Status unknown.
5 June 2021
Quick facts
| Lead sponsor | National Liver Institute, Egypt |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 5 June 2020 |
| Primary completion | 5 June 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Midodrine 2.5 mg tab — full drug profile →
Conditions studied
- Refractory Ascites — all drugs for Refractory Ascites →
- Children, Only — all drugs for Children, Only →
Sponsor
National Liver Institute, Egypt
Who can join
Adults 7 to 18, any sex, with Refractory Ascites or Children, Only. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ascites in liver cirrhosis is explained by increased production of vasoactive substances leading to renal vasoconstriction and salt and water retention. The retained water then accumulates in the peritoneal cavity under the effect of portal hypertension and low albumin. Refractory ascites is defined as ascites that cannot be mobilized or prevented from early recurrence after large-volume paracentesis despite medical therapy and dietary sodium restriction. Midodrine is an α1 receptor agonist that can improve systemic and renal hemodynamics in non-azotemic cirrhotic patients by counteracting mesenteric vasodilatation, which is accentuated in cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04043858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Liver Institute, Egypt trials
Trials by the same sponsor.
- NCT07331142 — CBD Stenting vs Non-Stenting for Choledocholithiasis · NA · completed
- NCT06948279 — Immediate vs. Elective Endoscopic Removal of Large CBD Stones in High-Risk Elderly Patients · NA · completed
- NCT07337291 — Double Stent for Biliary Stones in Cirrhotic Patients · NA · completed
- NCT05184491 — Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management · Phase 4 · unknown
- NCT06384443 — Proton Pump Inhibitors in Cirrhotic Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04043858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Liver Institute, Egypt
- Last refreshed: 24 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04043858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing